The small cohort size may also explain why the difference between the OS of patients with EG12 high versus EG12 low tumors did not reach statistical significance.
← all excerpts
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial.
1
—
—